Celltrion Initiates P-I Study of CT-P59 Against COVID-19 in Korea

 Celltrion Initiates P-I Study of CT-P59 Against COVID-19 in Korea

Celltrion Initiates P-I Study of CT-P59 Against COVID-19 in Korea

Shots:

  • The Korean MFDS has approved Celltrion’s IND to initiate a P-I trial of CT-P59 in patients with COVID-19. The company has initiated the enrollment and is set to evaluate the safety, tolerability, efficacy, PK, and immunogenicity of CT-P59 and anticipates the completion of study in Q3’20
  • The company anticipates the results of P-II & P-III in patients with mild symptoms, the P-III trial in patients with mod. to sev. COVID-19, and the prevention clinical trial, by the end of 2020
  • As part of the prevention study, Celltrion will enroll those who are in close contact with COVID-19 patients and those with no symptoms to evaluate the preventative effects of CT-P59

Click here ­to­ read full press release/ article | Ref: Celltrion | Image: The Conversation

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post